These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2975221)

  • 1. Sequentially alternating hormone chemotherapy with high-dose medroxy-progesterone acetate and low-dose epirubicin for the treatment of hormone-resistant metastatic prostatic cancer.
    Kontturi M; Sotarauta M; Tammela T; Lukkarinen O; Romppainen ML; Gröhn P
    Eur Urol; 1988; 15(1-2):43-7. PubMed ID: 2975221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study.
    Tveter KJ; Hagen S; Holme I; Klepp O; Kloster SE; Muri O; Poulsen C; Sander S; Sivertsen S; Urnes T
    Scand J Urol Nephrol; 1990; 24(4):243-7. PubMed ID: 2148830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life assessment in patients with hormone-resistant prostate cancer treated with epirubicin or with epirubicin plus medroxy progesterone acetate - is it feasible?
    van Andel G; Kurth KH; Rietbroek RL; van De Velde-Muusers JA
    Eur Urol; 2000 Sep; 38(3):259-64. PubMed ID: 10940698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential alternating medroxyprogesterone acetate and epirubicin in the treatment of advanced breast cancer.
    Smith JA; Green MD; Russell IS; Collins JP
    Aust N Z J Surg; 1989 Nov; 59(11):869-72. PubMed ID: 2530970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly low-dose adriamycin in hormone-resistant metastatic cancer of the prostate.
    Fosså SD; Urnes T; Kaalhus O
    Scand J Urol Nephrol; 1987; 21(1):13-6. PubMed ID: 2438753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer.
    Anderström C
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S97-100. PubMed ID: 7994797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer: a prospective randomized study.
    Anderström C; Eddeland A; Folmerz P; Hansson R; Milles S; Zachrisson B
    Eur Urol; 1995; 27(4):301-5. PubMed ID: 7656906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose medroxyprogesterone acetate versus prednisolone in hormone-resistant prostatic cancer. A pilot study.
    Fosså SD; Jahnsen JU; Karlsen S; Ogreid P; Haveland H; Trovåg A
    Eur Urol; 1985; 11(1):11-6. PubMed ID: 3157571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study.
    Johansson JE; Andersson SO; Holmberg L
    Br J Urol; 1991 Jul; 68(1):67-73. PubMed ID: 1831397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
    Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
    Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of medroxyprogesterone acetate, alone or in combination with epirubicin hydrochloride, on the growth of the Dunning R3327H prostatic adenocarcinoma.
    Landström M; Tomić R; Damber JE
    Eur Urol; 1987; 13(3):203-6. PubMed ID: 2956111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
    Mantovani G; Macciò A; Mulas C; Massa E; Madeddu C; Mura L; Contu P; Versace R
    Oncol Rep; 2002; 9(3):661-70. PubMed ID: 11956647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination chemotherapy using low-dose epirubicin and vindesine in patients with metastatic breast cancer].
    Takatsuka Y; Nakayama H; Kawahara T
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 1):667-71. PubMed ID: 2965547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose medroxyprogesterone in the treatment of advanced therapy-resistant prostatic carcinoma.
    Johansson JE; Lingårdh G
    Eur Urol; 1985; 11(1):9-10. PubMed ID: 3157573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly chemotherapeutic regimen in metastatic prostate cancer.
    Burk K
    Prog Clin Biol Res; 1990; 350():187-200. PubMed ID: 2201043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer. A study by the Italian Trials in Medical Oncology Group.
    Di Leo A; Bajetta E; Buzzoni R; Bochicchio AM; Nolè F; Biganzoli L; D'Aprile M; Veltri E; Comella G; Aitini E
    Am J Clin Oncol; 1995 Jun; 18(3):239-44. PubMed ID: 7538260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
    Mauriac L; Durand M; Bonichon F; Chauvergne J
    Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of epirubicin in advanced hormone-resistant prostatic carcinoma.
    Delaere KP; Leliefeld H; Peulen F; Stapper EW; Smeets J; Wils J
    Br J Urol; 1992 Dec; 70(6):641-2. PubMed ID: 1486391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action.
    Kim R; Osaki A; Tanabe K; Kojima J; Toge T
    Oncol Rep; 2001; 8(3):597-603. PubMed ID: 11295087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.